

31 March 2004

The Manager Company Announcements Australian Stock Exchange 4th Floor 20 Bridge Street SYDNEY NSW 2000

Dear Sir

TGA SUBMISSION ON TRACK FOR 7TH APRIL LODGMENT

Resonance Health is pleased to announce that its subsidiary company, Inner Vision Biometrics Pty Ltd. ("IVB") is on track for a 7th April lodgment of its submission to the Australian Therapeutic Goods Administration (TGA) for approval to market FerriScan.

FerriScan is a novel non invasive liver diagnosis technology designed to replace liver needle biopsies for the measurement of iron overload in the liver and with potentially broader application in other areas of liver disease such as fibrosis caused by hepatitis.

Under recently concluded reciprocal registration arrangements with European authorities, should FerriScan be included on the Australian Register of Therapeutic Goods (ARTG), immediate reciprocal registration in Europe can be obtained. The material assembled for the TGA submission in Australia will also form the basis for a U.S. FDA regulatory approval application for FerriScan planned for the second half of 2004.

The recently announced commercial collaboration between IVB and MedTel UK Ltd will facilitate the launching of FerriScan into the UK market with an experienced industry partner. Subject to obtaining the requisite regulatory approvals, commercial delivery of FerriScan in the UK and Australia is anticipated to commence in the second half of 2004.

Further information concerning Resonance Health and FerriScan can be obtained from our web sites at: www.resonancehealth.com www.ferriscan.com

Yours truly.

Tony Fitzgerald

Managing Director

For further information:	
Media / investor relations	Company
Rebecca Christie, Buchan	Mr Tony Fitzgerald, Managing Director
(02) 9293 2836	Resonance Health Limited
0417 382 391	(08) 9389 5933
rchristie@bcg.com.au	0418 903 647
	tfitzgerald@resonancehealth.com